BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why
BioMarin said that it would acquire Alesta for $275M upfront and up to $215M in development and regulatory milestones to bring ALE1 into its portfolio.
Stocktwits
More News
Everpure Stock Hits Record High – TD Cowen Says Oracle Could Be Its New Hyperscale Customer, Sees Meta Revenue Growth Ahead
TD Cowen raised its price target on Everpure stock to $170 from $100 and maintained a ‘Buy’ rating.
Stocktwits
HIMS Falls 6% After Hours On Q2 Loss— Eyes Oral Testosterone And Peptides Expansion
The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.
Stocktwits
CELH Stock On Track For Best Day In A Year After Post-Earnings Selloff — What’s Driving The Rally?
The billionaire founder of Rockstar Energy, Russ Savage, called for a leadership overhaul at Celsius.
Stocktwits
DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets
CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.
Stocktwits
Why Is HIMS Stock Down 13% Today?
The U.S. Federal Trade Commission on Wednesday sued the telehealth company over allegations it shared sensitive user health data with advertisers.
Stocktwits
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value
Bloomberg reported that Curium is discussing a deal that would pay roughly $102 per Lantheus share in cash upfront plus an additional $12.50 per share in contingent value rights.
Stocktwits
Should iShares Core S&P Mid-Cap ETF (IJH) Be on Your Investing Radar?
Style Box ETF report for IJH
Zacks
NVCR Stock Surges 28% For Best Day In Over 1.5 Years — What’s Driving The Rally?
The medical device maker, which develops Tumor Treating Fields (TTFields) therapy for cancer, said Q2 marked its strongest performance to date.
Stocktwits
Why Is HIMS Stock Rallying 13% Today?
An FDA advisory panel on Thursday recommended adding the peptide BPC-157 to a list that would allow compounding pharmacies to prepare it more freely for patients.
